key: cord-0833517-4lqxg90l authors: Neumann, Bernhard; Schmidbauer, Moritz L.; Dimitriadis, Konstatinos; Otto, Sören; Knier, Benjamin; Niesen, Wolf-Dirk; Hosp, Jonas A.; Günther, Albrecht; Lindemann, Sarah; Nagy, Gabor; Steinberg, Tim; Linker, Ralf A.; Hemmer, Bernhard; Bösel, Julian title: Cerebrospinal fluid findings in COVID-19 patients with neurological symptoms date: 2020-08-11 journal: J Neurol Sci DOI: 10.1016/j.jns.2020.117090 sha: c6c0290762fd383de4802305106e91b344033343 doc_id: 833517 cord_uid: 4lqxg90l • Biggest cohort of patients with COVID-19 and neurological symptoms who underwent LP. • In all 30 cases, RT-PCR for SARS-CoV-2 from CSF was negative. • CSF analysis findings, including WBC, were normal in most patients with COVID-19. • Neurological symptoms in COVID-19 seem to be caused mainly by indirect mechanism. Neurological symptoms in patients with severe acute respiratory syndrome coronavirus 2 (SARS- infection are commen [1] . SARS-CoV-2-RNA was detected by reverse-transcriptase-polymerase-chain-reaction (RT-PCR) in very few cases in cerebrospinal fluid (CSF) [2] as well as virus particles in autopsy brain samples in single cases [3] . This has prompted an ongoing controversy whether neurological symptoms are caused by viral infection of the CNS or via other mechanisms. We report the neurologic features along with CSF analysis findings in an observational series of 30 COVID-19 patients admitted to six tertiary referral centers in Germany from March until June 2020 as a selection from the register study PANDEMIC (Pooled Analysis of Neurologic DisordErs Manifesting in Intensive care of COVID- Frequent neurologic symptoms were altered mental state (10; 33 . 3%), new paresis (9; 30 . 0%), impaired consciousness (7; 23 . 3%), hypo-/areflexia (9; 30 . 0%), anosmia/hyposmia or ageusia/hypogeusia (6; 20 . 0%, underreported in critical care patients) and seizures (5; 16 . 7%) (table 1). Frequent neurologic diagnoses were encephalopathy (11; 36 . 7%), cerebrovascular events (5; 16 . 7%), and (poly)neuropathy (9; 30 . 0%) including one Miller-Fisher syndrome and two Guillain-Barré syndromes. Oligoclonal bands were negative in 14 of 25 tested cases (56 . 0%), in ten cases we found identical oligoclonal bands in CSF and serum (40 . 0%) and in the case of HSVE oligoclonal bands in CSF and serum with additional bands in CSF (4 . 0%) were detected. In all 30 cases, RT-PCR for SARS-CoV-2 from CSF was negative. Our clinical findings are in concordant with several other reports of autoimmune neuropathies [4] , the prevalence of cerebrovascular events [5] and the frequent occurrents of encephalopathies in patients with COVID-19. Cerebrovascular events might be explained by an endotheliitis during COVID-19 [6] and autoimmune neuropathies also argue rather for an indirect affection of the nervous system by para-infectious immune phenomena than direct involvement of the nervous system. A recently published case of encephalopathy with significant increase of interleukin-6 (IL-6) in CSF and clinical response to methylprednisolon without detection of SARS-CoV-2 in CSF supports the theory of an autoimmune mediated hyperinflammatory process as a mechanism in COVID-19 patients with neurological symptoms suspicious for an involvement of the CNS [7] . The absence of CSF findings specific for actual viral (meningo)encephalitis (e.g. increase WBC count) and lack of detection of SARS-CoV-2 by RT-PCR in the, up to date, biggest cohort of COVID-19 patients with , neurologic symptoms and LP in COVID-19 patients is another puzzle piece suggesting a more likely indirect affection of the nervous system, besides very rare cases of a possible direct affection by SARS-CoV-2. Our case series demonstrates that SARS-CoV-2 is usually not present in CSF of patients with neurological symptoms arguing against frequent active CNS invasion of the virus. Most neurological symptoms seem to be caused by indirect mechanisms such as cerebrovascular events, encephalopathies and neuropathies due to systemic critical illness and secondary immune phenomena. Reported detection of SARS-CoV-2-RNA or antibodies against the virus in the CSF in very few published cases may even be explained by dysfunction of the blood-CSF barrier or contamination with blood during difficult LP. Nevertheless, like in other virus infections of the brain, a negative PCR-test does not exclude the presence of the virus in the brain tissue. Therefore, further studies on antibodies against SARS-CoV2 in CSF would be useful. J o u r n a l P r e -p r o o f Journal Pre-proof Neurologic Features in Severe SARS-CoV-2 Infection A first case of meningitis/encephalitis associated with SARS-Coronavirus-2 Multiorgan and Renal Tropism of SARS-CoV-2 Guillain-Barré syndrome in the COVID-19 era: another occasional cluster? Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young Endothelial cell infection and endotheliitis in COVID-19 Frontal encephalopathy related to hyperinflammation in COVID-19